HLA Peptidome Analysis Strategies in Personalized Cancer Immunotherapy
- Support for low-input clinical samples (>10⁷ cells), including tumor biopsy and FFPE specimens.
- Dual analysis of HLA class I and class II presented peptides.
- Integration of NetMHCpan and de novo sequencing algorithms to enhance neoantigen discovery rates.
- High-resolution Orbitrap-based mass spectrometry ensuring high data quality and deep coverage.
- Multi-omics integration with proteomics and transcriptomics for comprehensive biological interpretation.
With the widespread application of immunotherapy in cancer treatment, strategies such as personalized tumor vaccines, TCR-T, and CAR-T therapies have become major research focuses. However, variability in therapeutic efficacy and the complexity of patient-specific immune responses have highlighted limitations in current precision immunotherapy approaches. In this context, HLA peptidome (immunopeptidome) analysis has emerged as a critical tool linking antigen processing with T cell recognition and is increasingly recognized as an essential platform for antigen discovery in tumor immunotherapy.
HLA Peptidome: A Central Mediator of Tumor Immune Surveillance
1. Definition of the HLA Peptidome
The HLA peptidome, also referred to as the immunopeptidome, represents the repertoire of short peptides presented on the cell surface by major histocompatibility complex (MHC) class I and class II molecules. These peptides originate from intracellular protein degradation and include a wide range of antigens, including tumor-derived mutant gene products (neoantigens). HLA peptidome analysis enables direct characterization of antigenic signals presented by tumor cells to the immune system.
2. Relationship to Transcriptomics and Proteomics
Although transcriptomic and proteomic data can provide information on gene and protein expression levels, they cannot determine whether peptides are processed and presented by MHC molecules. In contrast, HLA peptidome analysis directly identifies peptides that are naturally presented on MHC molecules and therefore represent bona fide candidates with immunogenic potential, forming a functional interface between antigen sources and T cell recognition.
Core Technological Workflow of HLA Peptidome Analysis
1. Immunoprecipitation-Based Enrichment of MHC Complexes
This step involves the enrichment of MHC molecules using specific antibodies such as W6/32. Applicable sample types include cell lines, tissue sections, and clinical tumor specimens. This process requires stringent experimental conditions to maintain the structural integrity of MHC complexes and prevent peptide dissociation.
2. Acid Elution and Peptide Purification
Peptides typically ranging from 8-12 amino acids in length are eluted from MHC complexes via acid treatment and subsequently purified using solid-phase extraction (SPE) to remove contaminants and interfering substances. This step is critical for ensuring high-quality downstream mass spectrometry data.
3. High-Resolution LC-MS/MS Analysis
High-resolution mass spectrometry platforms such as Orbitrap Exploris and Q Exactive are employed in combination with data-dependent acquisition (DDA) or data-independent acquisition (DIA) strategies to generate comprehensive HLA peptide repertoires. Due to their non-tryptic origin, low abundance, and high heterogeneity, HLA peptides pose significant challenges in terms of instrument sensitivity and resolution.
4. Specialized Computational Identification and Database Searching
Conventional proteomics search engines (e.g., SEQUEST and Mascot) are insufficient for accurate HLA peptide identification. Instead, dedicated computational pipelines such as NetMHCpan, MS-GF+, and PEAKS DB combined with de novo sequencing are required for peptide identification and MHC binding affinity prediction.
Applications in Personalized Cancer Immunotherapy
1. Neoantigen Identification and Personalized Vaccine Development
HLA peptidome analysis enables direct validation of whether somatic mutations are presented on the MHC surface, facilitating the identification of highly immunogenic and naturally presented neoantigens. This provides experimental evidence for the development of personalized cancer vaccines and improves the precision of therapeutic target selection.
2. Mechanistic Insights into Tumor Immune Evasion
Tumors may evade immune surveillance through downregulation of MHC expression or alterations in antigen processing pathways. HLA peptidome analysis can reveal loss or remodeling of presented epitopes, providing important insights into immune escape and tolerance mechanisms.
3. Target Validation for TCR-T and TIL Therapies
During the development of TCR-T and tumor-infiltrating lymphocyte (TIL) therapies, HLA peptidome data can be used to confirm the actual presentation of candidate epitopes, thereby reducing off-target risks and improving the rational selection of T cell receptors with optimal affinity and specificity.
HLA Peptidome Analysis Services at MtoZ Biolabs
At MtoZ Biolabs, we integrate high-sensitivity mass spectrometry platforms, optimized immunopeptidome enrichment workflows, and customized bioinformatics pipelines to provide a comprehensive HLA peptidome analysis service covering all stages from sample preparation to peptide identification, immunogenicity prediction, and target validation.
Key technical features include:
We are committed to providing robust, reproducible, and translational immunopeptidomics solutions for academic researchers and biotechnology companies, enabling reliable immune target discovery.
HLA peptidome analysis serves as a critical interface between tumor antigen presentation and T cell recognition and is rapidly becoming a cornerstone of personalized cancer immunotherapy. With continuous advancements in mass spectrometry sensitivity and computational algorithms, its applications in precision target discovery, immune monitoring, and resistance mechanism elucidation are expected to expand further. MtoZ Biolabs remains dedicated to advancing proteomics and immunopeptidomics technologies to support scientific innovation and clinical translation.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
